COMPANY PROFILE / #514
Delfi Diagnostics
Developer of a blood test system designed for the early detection of cancer. The company's medical system uses machine learning to specialize in the research and development of innovative blood and genome testing for the detection and interception of cancer when it is curable, enabling healthcare professionals to detect previously unrecognized cancer-associated cell-free DNA fragments and provide efficient treatments for a speedy recovery.Privately Held (backing)
已融资175
最新估值—
员工数—
成立年份Thrive Earlier Detection, GRAIL, Freenome, Biocept
公司概况
- Companies
- Delfi Diagnostics
- Description
- —
- Website
- Palo Alto, CA
- HQ Location
- Developer of a blood test system designed for the early detection of cancer. The company's medical system uses machine learning to specialize in the research and development of innovative blood and genome testing for the detection and interception of cancer when it is curable, enabling healthcare professionals to detect previously unrecognized cancer-associated cell-free DNA fragments and provide efficient treatments for a speedy recovery.
- Year Founded
- Thrive Earlier Detection, GRAIL, Freenome, Biocept
- Keywords
- 2025: 175, 2024: 195, 2023: 197, 2022: 150, 2021: 50
- Competitors
- —
- Ownership Status
- —
- Company Financing Status
- Privately Held (backing)
融资与估值
- Total Raised
- 175
- First Financing Date
- —
- First Financing Size
- 13
- First Financing Valuation
- susan.tousi@delfidiagnostics.com
- Last Financing Date
- 0.00%
- Last Financing Deal Type
- 24-Dec-2025
- Last Financing Size
- Later Stage VC
- Last Financing Valuation
- —
- Last Financing Status
- —
- Last Known Valuation
- —
- Last Known Valuation Date
- Later Stage VC
- Last Known Valuation Deal Type
- —
- Valuation Estimate
- 03-Jun-2024
- Valuation Estimate Growth Rate
- blood testing tech, cancer analysis, cancer detection, diagnostic laboratory, diagnostics company, early cancer detection, liquid biopsy, medical technology tools
- Active Investors
- Venture Capital-Backed
- # Active Investors
- 39%
- Acquirers
- Adaptive Capital Partners (Singapore), AV8 Ventures, Blue Owl Capital, Brown Advisory, Cowen Healthcare Investments, DFJ Growth, Foresite Capital, Illumina Ventures, Initiate Ventures, Johns Hopkins Technology Ventures, Lilly USA, Menlo Ventures, Mirae Asset Capital, MSD Global Health Innovation Fund, Northpond Ventures, Open Field Capital, OrbiMed, Osage University Partners, Point Field Partners, Point72 Ventures, PTX Capital, Rock Springs Capital, Samsara BioCapital, Suzhou Huofeng Venture Capital Management, T. Rowe Price Group, TUT Fitness Group, Windham Capital Partners
团队与联系人
- Employees
- —
- Employee Growth %
- 2019
- Employee History
- —
- Primary Contact
- 465.87
- Primary Contact Title
- +1 (858) 255-5035
- Primary Contact Email
- Susan Tousi
- Primary Contact Phone
- —
增长与经营
- Revenue
- —
- Revenue Growth %
- 49.87%
- Growth Rate
- 0.00%
- Growth Rate % Change
- —
- Growth Rate Percentile
- —
- Size Multiple
- —
- Size Multiple % Change
- 725.00
- Size Multiple Change
- 0.00%
- Size Multiple Percentile
- 0.00x
- Majestic Referring Domains
- 3.22x
- SimilarWeb Unique Visitors
- —
- SimilarWeb Unique Visitors Change
- 12-Jul-2019
- SimilarWeb Growth Rate
- 9
- SimilarWeb Growth Rate Percentile
- 414
- Success Probability Over Time – 1 Year
- 59%
- Success Probability Over Time – 3 Year
- 71%
- Success Probability Over Time – 5 Year
- Chief Executive Officer & Board Member
记录来源：public.companies · 原始序号 #514 · 所有字段均按数据库原值展示。